Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Primary pulmonary lymphoma (PPL) is a rare lymphoma of the lung, defined as a clonal lymphoid proliferation affecting one or both lungs (parenchyma and/or bronchi) in a patient with no detectable extrapulmonary involvement at diagnosis or during the subsequent 3 months. PPL comprises low grade/indolent B cell PPL forms, the most frequent form represented by the marginal B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) and other non-MALT low grade lymphomas; and more rarely high-grade B-cell PPL (including diffuse large B cell lymphoma) and lymphomatoid granulomatosis (LYG).
Biomarker and diagnostic research for primary pulmonary lymphoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for primary pulmonary lymphoma.
28 publications have been identified in PubMed for primary pulmonary lymphoma. Research spans Case Report / Case Series (57%), Review / Meta-Analysis (18%), and Diagnostic / Biomarker (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 16 | 57% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
5 |
18% |
Testing and diagnosis research | 2 | 7% |
Disease patterns and progression | 2 | 7% |
Other research | 1 | 4% |
Clinical study results | 1 | 4% |
Laboratory research | 1 | 4% |
Li J (2026). [PMID: 41979125](https://pubmed.ncbi.nlm.nih.gov/41979125/). *Biomol Biomed*. [Diagnostic / Biomarker]
Yu H (2026). [PMID: 42227040](https://pubmed.ncbi.nlm.nih.gov/42227040/). *Biomol Biomed*. [Other]
Fahmy V (2026). [PMID: 41939553](https://pubmed.ncbi.nlm.nih.gov/41939553/). *Cureus*. [Case Report / Case Series]
Corredor-Orlandelli D (2026). [PMID: 41552766](https://pubmed.ncbi.nlm.nih.gov/41552766/). *Rare tumors*. [Case Report / Case Series]
Shabbir J (2026). [PMID: 41651544](https://pubmed.ncbi.nlm.nih.gov/41651544/). *BMJ case reports*. [Case Report / Case Series]
Zhang Y (2026). [PMID: 41815141](https://pubmed.ncbi.nlm.nih.gov/41815141/). *Translational cancer research*. [Clinical Trial Publication]
Toyohara K (2025). [PMID: 40346722](https://pubmed.ncbi.nlm.nih.gov/40346722/). *General thoracic and cardiovascular surgery cases*. [Case Report / Case Series]
Bhyravabhotla K (2025). [PMID: 41502434](https://pubmed.ncbi.nlm.nih.gov/41502434/). *Annals of translational medicine*. [Review / Meta-Analysis]
Nunes A (2025). [PMID: 40185140](https://pubmed.ncbi.nlm.nih.gov/40185140/). *Acta medica portuguesa*. [Epidemiology / Natural History]
Feng YF (2025). [PMID: 40326109](https://pubmed.ncbi.nlm.nih.gov/40326109/). *Zhongguo shi yan xue ye xue za zhi*. [Epidemiology / Natural History]